FDA animal data efficacy rule
This article was originally published in The Tan Sheet
Executive Summary
Drugs may be approved for human use based solely on animal data in cases where human testing is not feasible or ethical, according to FDA final rule published in May 31 Federal Register. Under the reg, drugs used "to reduce or prevent the toxicity of chemical, biological, radiological or nuclear substances" may be approved for marketing "based on evidence of effectiveness derived only from appropriate animal studies and any additional supporting data," agency says. Reg is part of FDA's effort to help improve nation's ability to respond to emergencies, including terrorist events; notice comes shortly after Congress passed bioterrorism bill (1"The Tan Sheet" May 27, 2002, p. 18)...
You may also be interested in...
Potassium Iodide Stockpiling Guidelines Called For In Bioterrorism Bill
Within a year of enacting bioterrorism legislation, the Bush Administration will consult with federal, state and local agencies to establish guidelines for the stockpiling of potassium iodide (KI) tablets
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.